Searchable abstracts of presentations at key conferences in endocrinology

ea0052p08 | (1) | UKINETS2017

Audit of a new nurse-led non-medical prescribing (NMP) clinic for systemic anti-cancer agents (SACTs)

Davies Philippa , Quaglia Elizabeth , McSweeney Aisling , Caplin Martyn , Thirlwell Christina

The number of people diagnosed and living with cancer in the UK continues to rise and this also places increasing demands on specialist cancer care services (NHS England 2015). Neuroendocrine Tumours (NETs) incidence and prevalence increases alongside this demand (PHE 2016). NETs still remain a rare cancer with specialist needs and the clinical nurse specialist (CNS) team are ideally placed to support these patients. Oncology clinics are becoming increasingly pressured and the...

ea0077lb50 | Late Breaking | SFEBES2021

A plasma and serum 5-HIAA assay with comparable diagnostic performance in patients with neuroendocrine tumours

Ewang-Emukowhate Mfon , Subramaniam Krithika , Grossman Ashley , Lam Francis , Nair Devaki , Caplin Martyn

Introduction: Neuroendocrine tumours (NET) are a diverse group of neoplasms originating from cells within the diffuse endocrine system. Urine 5-HIAA is commonly used in the diagnosis and monitoring of patients with NET in particular small intestinal neuroendocrine tumour with carcinoid syndrome. Urine 5-HIAA collection over a 24 hour period and the potential exposure to acid preservative in the sample container, limit the use of urine 5-HIAA.Methods: Sam...

ea0087oc2 | Oral Communications | UKINETS2022

Glucagonomas: diagnostic features and outcomes of first line treatment in a series of 18 patients

Porto Juliana , Branton Alexander , Heseth Richard , Mandair Dalvinder , Caplin Martyn , Toumpanakis Christos

Introduction: Glucagonomas are rare functional pancreatic neuroendocrine tumours (p NETs), with an annual occurrence of 0.01 to 0.1 new cases per 100,000. Objective: We focused on presenting symptoms, primary’s size and location, presence of metastases, biomarkers at diagnosis, histology, response to first line treatment (clinical and biochemical), disease fee survival (DFS) and PFS (progression free survival). Methods: Eighteen pa...

ea0087p14 | Poster Presentations | UKINETS2022

Somatostatin receptors in olfactory neuroblastoma: The rationale for peptide receptor radionuclide therapy

Porto Juliana , Hayes Aimee , Branton Alexander , Caplin Martyn , Alusi Martyn , Grossman Ashley

Olfactory neuroblastoma (ONB) is a rare neuroendocrine tumour with a slow onset of symptoms, and classically a propensity for recurrence and a poor prognosis. Due to its rarity, there is no agreed standard therapy, but treatment will usually include surgical resection, adjuvant radiotherapy and/or chemotherapy. However, such tumours very often show positive uptake on somatostatin receptor radionuclide scanning, and selective use of peptide receptor radionuclide therapy (PRRT) ...

ea0068oc1 | Abstracts | UKINETS2019

Longitudinal biomarker changes during treatment of functional midgut neuroendocrine tumours with lanreotide autogel: CALM-NET study results

Shah Tahir , Caplin Martyn , Khan Mohid S , Houchard Aude , Higgs Kate , Meyer Tim

Background: CALM-NET (EudraCT 2013-002194-22; NCT02075606), a prospective, exploratory study, evaluated enumeration of pre-treatment circulating tumour cells as a predictor of symptomatic response to lanreotide autogel (LAN) in patients with functional midgut neuroendocrine tumours (NETs). Here, we describe the effect of LAN on biomarkers.Methods: Patients, ≥18 years, with functional, well- or moderately-differentiated midgut NETs were treated with...

ea0072p3 | (1) | UKINETS2020

Circulating biomarkers to predict progression-free survival in patients with neuroendocrine tumours received 177Lu-DOTATATE

Chen Luohai , Gnanasegaran Gopinath , Mandair Dalvinder , Toumpanakis Christos , Caplin Martyn , Navalkisoor Shaunak

Background: 177Lu-DOTATATE is increasingly used in patients with advanced neuroendocrine tumour (NET). However, few circulating biomarkers are available to predict progression-free survival (PFS) of patients received 177Lu-DOTATATE.Materials and methods: Clinicopathological data and data of baseline circulating biomarkers including neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), e...

ea0077p214 | Neuroendocrinology and Pituitary | SFEBES2021

Pregnancy and neuroendocrine neoplasms

Ratnayake Gowri M , Armonis Panagiotis , Hayes Aimee R , Mandair Dalvinder , Khoo Bernard , Toumpanakis Christos , Grossman Ashley B , Caplin Martyn E

Background: The incidence of neuroendocrine neoplasms (NENs) in younger populations (<50 years) is increasing and was 1.8 per 100,000 persons in 2011. There is limited data on NENs and pregnancy.Methods: A retrospective analysis was performed on pregnant women with NENs managed in an ENETS Centre of Excellence. The objectives of the study were to describe the tumour characteristics, pregnancy outcomes, treatment and the tumour behaviour intra-pregnan...

ea0052p23 | (1) | UKINETS2017

Above-label doses of lanreotide Autogel for the treatment of advanced neuroendocrine tumours (NETs)

Laskaratos Faidon-Marios , Banks Jamie , Shah Ruchir , Smith Jack , Jacobs Ben , Galanopoulos Michalis , Caplin Martyn , Mandair Dalvinder , Toumpanakis Christos

Introduction: High doses/frequency of somatostatin analogues (SSA) are often used to control refractory functional symptoms and/or tumour progression in patients treated with standard doses of SSAs, but there is limited evidence for the efficacy of this strategy.Methods: Retrospective analysis of 47 NET patients on lanreotide Autogel 120 mg every 3 weeks (as monotherapy). Progression-free survival (PFS) and clinical outcomes were assessed. A 30% change i...

ea0052p24 | (1) | UKINETS2017

Shortened interval of octreotide LAR administration for the treatment of advanced neuroendocrine tumours (NETs)

Laskaratos Faidon-Marios , Shah Ruchir , Banks Jamie , Jacobs Ben , Smith Jack , Galanopoulos Michalis , Mandair Dalvinder , Caplin Martyn , Toumpanakis Christos

Introduction: Escalated doses of octreotide LAR are commonly used to control functional symptoms and/or tumour growth, but there is limited evidence regarding the efficacy of this approach.Methods: Retrospective analysis of 69 NET patients treated with octreotide LAR 30 mg every 3 weeks (as monotherapy). Progression-free survival (PFS) and clinical outcomes were assessed. A 30% change in symptomatology and biomarker levels was considered significant....

ea0080p1 | Abstracts | UKINETS2021

Setting up of a national liver transplant programme for neuroendocrine tumour liver metastases in UK and Ireland: opportunities for clinical study and research

Shah Tahir , Moore Joanna , Venkataraman Hema , Caplin Martyn , Smith Stacey , O'Toole Dermot , Hoti Emir , Dasari Bobby , Ford Samuel , Mazzaferro Vincenzo , Gibbs Paul , Manas Derek , Isaac John , Thorburn Douglas

Background: Transplantation for cancer indications is evolving rapidly in UK and Ireland. Liver transplantation [LT] for unresectable neuroendocrine tumour liver metastases [NET LM] is one of three new cancer indications. It has the potential to significantly improve survival outcomes however, transplant benefit has likely been achieved only by highly experienced Centre(s). Since eligible patients for transplantation also have excellent prognosis with standard management, care...